CLG 561

Drug Profile

CLG 561

Alternative Names: CLG-561

Latest Information Update: 05 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alcon
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dry age-related macular degeneration

Most Recent Events

  • 10 Aug 2015 Alcon Research plans a phase II trial for Dry age-related macular degeneration in USA (NCT02515942)
  • 01 Nov 2014 Alcon Research completes a phase I trial in Dry age-related macular degeneration in USA (NCT01835015)
  • 31 May 2013 Phase-I clinical trials in Dry age-related macular degeneration in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top